Application of homoplantaginin in preparation of medicine for preventing and treating AIDS
Through the research and development of Gaocaibin, the mechanism of action of inhibiting HIV-1 reverse transcriptase and protease was used to solve the problems of resistance and side effects of existing HIV drugs, and provide low-toxic and efficient anti-HIV drugs development direction.
Patent Information
- Application Number
- CN202411454019.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-17
- Publication Date
- 2024-12-03
AI Technical Summary
The existing HIV drugs have drug resistance, strong side effects, enhanced dependence and have failed to effectively cure AIDS. It is urgent to develop new anti-HIV drugs that are efficient and low-toxic.
Using Gaochebinol as the main component, by preparing Gaochebinol derivatives or compound drugs, its anti-HIV-1 activity is studied, and combining multiple cell infection models, its potential mechanism of action is studied in-depth to develop multi-target anti-HIV drug.
Gaochebinoside significantly inhibits HIV-1 activity by inhibiting reverse transcriptase and protease during HIV-1 replication, and has strong anti-HIV-1 activity and low toxicity, providing a new direction for the development of anti-HIV drugs, solving the problem. Problems with drug resistance and side effects of existing drugs.
Smart Images

Figure CN119055667A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of research and development of AIDS therapeutic drugs, and in particular relates to the application of psyllium glucoside in the preparation of AIDS prevention and treatment drugs. Background Art
[0002] According to the latest statistics recently released by the Centers for Disease Control and Prevention, in 2021, there were 60,154 cases of acquired immune deficiency syndrome (AIDS) and 19,623 deaths, with an incidence rate of 4.2669 / 100,000 and a mortality rate of 1.3919 / 100,000, ranking first among Class A and B infectious diseases. At present, although there are more than 30 anti-HIV drugs in six categories, anti-HIV (human immune deficiency virus, HIV) drugs used in clinical treatment still have many defects, such as residual viruses in the patient's body, increased drug resistance of the virus, increased dependence on drugs, and the need to take drugs continuously, and endure the various toxic side effects brought by the drugs. So far, no effective cure has been developed in the world, so the development of new anti-HIV drugs is urgent.
[0003] HIV is an RNA virus belonging to the family Retroviridae and the genus Lentivirus. During HIV infection, HIV-1 outer membrane glycoprotein gp120 specifically binds to the CD4 receptor on the surface of T4 lymphocytes and adsorbs to the cells. With the assistance of auxiliary receptors CCR5 or CXCR4, HIV-1 outer membrane glycoprotein gp41 fuses with the host cell membrane to allow the virus particles to enter the cell, and then remove the capsid to expose the nucleic acid. Under the catalysis of viral reverse transcriptase and ribonuclease H, HIV-1 single-stranded RNA is reverse transcribed into single-stranded DNA, and then catalyzed into double-stranded DNA by cellular polymerase in the cell nucleus. HIV-1 integrase integrates the double-stranded DNA provirus into the chromosome of the host cell, forming a latent infection of HIV-1. The viral mRNA synthesized with the integrated viral DNA as a template translates into large fusion polyproteins, and then under the action of viral proteases, these polyproteins are spliced and processed to form mature viral structural proteins. Since HIV is prone to mutation during replication, and the specific HIV inhibitors currently used usually have a narrow antiviral spectrum, it is easy to develop drug resistance. Therefore, it is urgent to develop new compounds with high efficiency, low toxicity and low drug resistance rate to cope with the changes of HIV.
[0004] Homoplanin (Hom) is extracted from the lychee grass of the genus Salvia of the Labiatae family and belongs to the flavonoids. Lychee grass is also known as toad grass, snow primrose, wrinkled fur grass, frog grass, etc. It was first recorded in the Compendium of Materia Medica. It is cool in nature and bitter in taste. It has the effects of clearing heat, detoxifying, cooling blood, stopping bleeding, and diuresis. Studies have shown that lychee grass has anti-inflammatory, antioxidant, antibacterial and antiviral pharmacological effects. It is used for sore throat, bronchitis, edema of nephritis, carbuncle, external treatment of mastitis, hemorrhoids, bleeding and other diseases. It is produced in all places except Xinjiang, Gansu, Qinghai and Tibet. Homoplanin is one of the main components of lychee grass and belongs to the flavonoids. Flavonoids have always been the focus of drug research and have demonstrated their wide biological activity. Many literatures have reported their antiviral ability. Rhus succedanea (Anacardiaceae) methanol extract containing the flavonoids robustaflavonoids and cyperiflavonoids inhibited the polymerase activity of HIV-1RT. WikstrolB is another biflavonoid isolated from the extract of the root of Wikstroemia indica (Thymelaeaceae) with anti-HIV-1 activity. Isoflavones and pterostilbene from plants of the genus Erythrina have been found to have anti-HIV activity. Xanthohumol obtained from Humulus lupulus also inhibits HIV-1.
[0005] The anti-HIV activity of psyllium glycosides has not been reported. Previous pharmacological studies have shown that it has a variety of pharmacological effects, including antitussive and antiasthmatic, treatment of liver damage, improvement of endothelial insulin tolerance, inhibition of tumor growth, anti-osteoporosis, induction of cancer cell apoptosis, inhibition of a-glucosidase, etc. Other experiments have shown that psyllium glycosides have the effects of lowering blood sugar and regulating blood lipids, can significantly improve the production of NO, and can improve endothelial insulin resistance caused by free fatty acids. It may protect endothelial cells by inhibiting the production of reactive oxygen species. Its mechanism of action is related to anti-oxidative stress and has anti-angiogenic effects. Summary of the invention
[0006] In order to solve the problem that most HIV drugs in the prior art are single-target inhibitors, and clinically a combination of multiple drugs (HAART) is mainly used to improve the antiviral efficacy, which has the disadvantages of strong side effects and high drug resistance, the present invention provides a new use of homoplanin, and uses multiple cell virus infection models to deeply study the anti-HIV-1 activity of homoplanin from lychee grass extract, providing a theoretical basis for the development of new anti-HIV-1 drugs with originality and independent intellectual property rights, which can be applied to the further development and application of anti-HIV drugs; to achieve the above purpose, the present application proposes the use of homoplanin in the preparation of drugs for the prevention and treatment of AIDS, and homoplanin is used to prepare homoplanin derivatives or composite drugs containing homoplanin, and the structural formula of the homoplanin is as follows:
[0007]
[0008] Furthermore, the AIDS is HIV-1 type.
[0009] Furthermore, the homoplanin is combined with pharmaceutically acceptable excipients to form a preparation.
[0010] Furthermore, the dosage forms of the preparation include injection, capsule, tablet, granule, dragee, and solution.
[0011] Further, the dosage form includes commonly used excipients and pharmaceutical excipients;
[0012] The commonly used excipients include fillers and solubilizers, binders, humectants, disintegrants, absorbents, and lubricants;
[0013] The pharmaceutical excipients include solid, semi-solid and liquid forms.
[0014] Compared with the prior art, the advantages and effects of this application are as follows:
[0015] 1. This invention is the first to conduct research on the anti-HIV-1 activity of homoplanin, and uses three cell infection systems in HIV-1 virus strains with different tropisms and combines experiments to reveal the potential anti-HIV mechanism of the two, which is original and innovative.
[0016] 2. The key point of the present invention is to use a variety of cell lines and different tropic viruses to carry out activity experiments of homoplanin against HIV-1, and reveal the potential mechanism of action of homoplanin, with the aim of further studying the anti-HIV medicinal potential of homoplanin, in order to discover highly effective, low-toxic and inexpensive multi-target anti-HIV drugs, solve the current dilemma of clinical AIDS treatment, and lay the foundation for further exploring the clinical value of homoplanin in the future.
[0017] 3. The present invention has found that homoplanin mainly exerts its anti-HIV-1 effect by inhibiting reverse transcriptase and protease during HIV-1 replication. In addition, the present invention uses three cell infection models and finds that homoplanin has strong anti-HIV-1 activity. Three virus infection models were constructed by three cells and two virus strains to carry out in vitro pharmacology experiments, further clarifying the inhibitory effect of homoplanin on the replication of HIV-1 with different tropisms.
[0018] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application so that it can be implemented in accordance with the contents of the specification, and to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the following is a detailed description of the preferred embodiments of the present application in conjunction with the accompanying drawings as follows.
[0019] Based on the detailed description of the specific embodiments of the present application in combination with the accompanying drawings below, those skilled in the art will become more aware of the above and other objects, advantages and features of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can also be obtained based on these drawings without creative work. In all drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, each element or part is not necessarily drawn according to the actual scale.
[0021] in:
[0022] Figure 1 This is a schematic diagram of the structural formula of psyllium glycoside.
[0023] Figure 2 This is a flow chart of the anti-HIV-1 mechanism of action of psyllium glycosides.
[0024] Figure 3 Is homophytoside in TZM-bl-HIV-1 IIIB Schematic diagram of cytotoxicity and anti-HIV-1 activity in cell infection models:
[0025] 3A: TZM-bl cytotoxicity dose-response curve of homophyllidine;
[0026] 3B: Homophytoside in TZM-bl-HIV-1 IIIB Dose-response curves of anti-HIV-1 activity in cellular infection models;
[0027] 3C: TZM-bl cytotoxicity dose-response curve of AZT;
[0028] 3D: AZT in TZM-bl-HIV-1 IIIB Dose-response curves for anti-HIV-1 activity in a cellular infection model.
[0029] Figure 4 Is homophytoside in MT-2-HIV-1 IIIB Schematic diagram of cytotoxicity and anti-HIV-1 activity in cell infection models:
[0030] 4A: MT-2 cell cytotoxicity dose-response curve of homoplanin;
[0031] 4B: Homophytoside in MT-2-HIV-1 IIIB Dose-response curves of anti-HIV-1 activity in cellular infection models;
[0032] 4C: MT-2 cell cytotoxicity dose-response curve of AZT;
[0033] 4D: AZT in MT-2-HIV-1 IIIB Dose-response curves for anti-HIV-1 activity in a cellular infection model.
[0034] Figure 5 Schematic diagram of the cytotoxicity and HIV-1p24 levels of homoplanin (A) and AZT (B) in PBMCs.
[0035] Figure 6 This is a schematic diagram of the inhibitory effect of psyllium on HIV-1-induced CPE.
[0036] Figure 7 This is the result of the inhibitory effect of psyllium on the key enzyme activity of HIV-1 virus:
[0037] 7A: Effect of homoplanin on HIV-1 RT activity, with NVP as a positive drug control;
[0038] 7B: Effect of homoplanin on HIV-1PR activity, with Pepstatin A as a positive drug control;
[0039] 7C: Effect of homoplanin on HIV-1 IN activity, with sodium azide as positive drug control. Specific embodiments
[0040] To make the purpose, technical scheme and advantages of the embodiment of the present application clearer, the technical scheme in the embodiment of the present application will be clearly and completely described below in conjunction with the accompanying drawings in the embodiment of the present application. Obviously, the described embodiment is a part of the embodiment of the present application, rather than all of the embodiments. In the following description, specific details such as specific configuration and components are provided only to help fully understand the embodiments of the present application. Therefore, it should be clear to those skilled in the art that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of the present application. In addition, for clarity and brevity, the description of known functions and structures is omitted in the embodiment.
[0041] It should be understood that the references to "one embodiment" or "this embodiment" throughout the specification mean that the specific features, structures, or characteristics associated with the embodiment are included in at least one embodiment of the present application. Therefore, the references to "one embodiment" or "this embodiment" appearing throughout the specification do not necessarily refer to the same embodiment. In addition, these specific features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0042] In addition, the present application may repeat reference numerals and / or letters in different examples. This repetition is for the purpose of simplicity and clarity, and does not in itself indicate the relationship between the various embodiments and / or settings discussed.
[0043] The term "and / or" in this article is only a description of the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can mean: A exists alone, B exists alone, and A and B exist at the same time. The term " / and" in this article describes another type of association object relationship, indicating that there can be two relationships. For example, A / and B can mean: A exists alone, and A and B exist alone. In addition, the character " / " in this article generally indicates that the associated objects before and after are in an "or" relationship.
[0044] The term "at least one" in this article is merely a description of the association relationship of associated objects, indicating that there may be three relationships. For example, at least one of A and B can mean: A exists alone, A and B exist at the same time, and B exists alone.
[0045] It should also be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusions.
[0046] Example 1
[0047] This example introduces the application of psyllium glycosides in the preparation of drugs for the prevention and treatment of AIDS. Figure 1 As shown, homoplanin is used to prepare homoplanin derivatives or composite drugs containing homoplanin, and the structural formula of the homoplanin is as follows:
[0048]
[0049] Furthermore, the AIDS is HIV-1 type.
[0050] Furthermore, the homoplanin can be mixed with conventional adjuvants to prepare various dosage forms for prevention or treatment. Injections, capsules, tablets, granules, dragees, solutions, etc. are all available pharmaceutical dosage forms. Dosage forms such as capsules, tablets, granules, dragees, solutions, etc. can be prepared by known conventional methods.
[0051] Furthermore, dosage forms such as capsules, tablets, granules, and dragees may contain one or more commonly used excipients: fillers and solubilizers: such as starch, microcrystalline cellulose, etc.; binders: such as carboxymethyl cellulose, polyvinyl pyrrolidone, etc.; humectants: such as glycerol; disintegrants: such as calcium carbonate, etc.; absorbents: such as kaolin, etc.; lubricants: such as talc, etc.
[0052] Furthermore, pharmaceutical excipients may be in various forms such as solid, semisolid, liquid, etc., and formulation adjuvants may be of various types.
[0053] Furthermore, the solution may contain common solvents, solubilizers, emulsifiers, preservatives, etc., such as water, ethanol, glycerol, polyethylene glycol, benzyl benzoate, etc.
[0054] Example 2
[0055] This example introduces the mechanism of action of psyllium glycosides in anti-AIDS drugs. Please refer to Figure 2 As shown, based on the above embodiment, the present embodiment adopts the following technical scheme: using TZM-bl-HIV-1 IIIB MT-2-HIV-1 IIIB and peripheral blood mononuclear cells PBMCs-HIV-1 BaL Three cell virus infection models were used to verify the anti-HIV activity of psyllium glycosides, and the drug's target was detected experimentally to explore the anti-HIV-1 mechanism of action of psyllium glycosides.
[0056] Experiment 1: Cytotoxicity and anti-HIV-1 activity of homoplanin in TZM-bl cells
[0057] (1) Cytotoxicity assay
[0058] Collect TZM-bl cells after trypsin digestion, adjust the concentration to 1×105 cells / ml with DMEM complete culture medium, and inoculate them into 96-well cell culture plates at a volume of 100μl / well. Culture in a 37°C, 5% CO2 incubator. The next day, add serially diluted compounds (40μl / well), and set up 3 replicate wells at the same concentration. At the same time, use cells without compound treatment as negative controls, and culture medium as background controls. Add culture medium to each well to a total volume of 200μl. Place the cell culture plate in the incubator and continue culturing for 48h, then add 20μl / well of The cell viability detection reagent was shaken for 3 minutes, placed in a 37°C, 5% CO2 incubator for incubation for 10 minutes, and finally the luminescent signal was detected on a multifunctional microplate reader, and the relative cell activity was calculated according to the following formula: cell activity (%) = (luminescence value of the experimental well-luminescence value of the background well) / (luminescence value of the negative control well-luminescence value of the background well) × 100%.
[0059] (2) Antiviral activity test
[0060] TZM-bl cells were collected after trypsin digestion, adjusted to a concentration of 1×105 cells / ml with DMEM complete culture medium, and inoculated into a 96-well cell culture plate at a volume of 100 μl / well. Cultured in a 37°C, 5% CO2 incubator. The next day, 100 TCID50 of HIV-1 IIIB Virus dilution (60 μl / well) and serially diluted compounds (40 μl / well) were added, and three replicate wells were set at the same concentration. Positive control wells were added with virus only, and negative control wells were added with neither compound nor virus, and then the culture medium was added to a total volume of 200 μl / well. After the cell culture plate was placed in the incubator and cultured for 48 hours, 20 μl / well of Bright-Glo TM Luciferase detection reagent was shaken for 3 minutes, and then the luminescent signal was detected by a multifunctional microplate reader, and the relative virus level was calculated according to the following formula: relative virus level (%) = (luminescent value of experimental well - luminescent value of negative control well) / (luminescent value of positive control well - luminescent value of negative control well) × 100%.
[0061] (3) Experimental results
[0062] The ATP method was used to detect cell viability to reflect the cytotoxicity of the compound. When the cell viability was <80%, the compound was considered to be cytotoxic. Figure 3 As shown in the results, the relative activity of TZM-bl cells treated with homophyllidine was greater than 80%, and no obvious toxic effect on TZM-bl cells was observed; at a concentration that did not affect cell activity, homophyllidine could inhibit HIV-1 in a dose-dependent manner. IIIB In TZM-b1, the relative viral load decreased with the increase of drug concentration, i.e., the inhibition rate increased. Under the treatment of the standard control drug AZT, the relative viral level of HIV-1 decreased, showing a good dose-dependency.
[0063] Example 3
[0064] This example introduces the mechanism of action of psyllium glycosides in anti-AIDS drugs. Please refer to Figure 4 As shown, further introduction is given based on the above embodiments:
[0065] Experiment 2: Cytotoxicity and anti-HIV-1 activity of homoplanin in MT-2 cells.
[0066] (1) Cytotoxicity assay
[0067] Take MT-2 cells in the logarithmic growth phase and adjust the concentration to 2×10 5 / ml, inoculated in a 96-well cell culture plate at a volume of 160μl / well. At the same time, add serially diluted compounds (40μl / well), and set up 3 replicate wells at the same concentration. Cells without compound treatment were used as negative controls, and culture medium was used as background control. The culture medium was supplemented to a total volume of 200μl. After the cell culture plate was placed in the incubator and cultured for 72h, 20μl / well of The cell viability detection reagent was shaken for 3 minutes, placed in a 37°C, 5% CO2 incubator for incubation for 10 minutes, and finally the luminescent signal was detected on a multifunctional microplate reader, and the relative cell activity was calculated according to the following formula: cell activity (%) = (luminescence value of the experimental well-luminescence value of the background well) / (luminescence value of the negative control well-luminescence value of the background well) × 100%.
[0068] (2) Antiviral activity test
[0069] MT-2 cells in the logarithmic growth phase were taken and 3.2×10 4 The cells were inoculated into 96-well cell culture plates at a density of 100 μl / well. Serially diluted compounds (40 μl / well) and 320 TCID50 of HIV-1 IIIB The virus dilution solution was added to make the total volume of each well 200 μl, and three replicate wells were set at the same concentration. The positive control wells were added with only virus, and the negative control wells were not added with both compound and virus, and then the culture medium was added to a total volume of 200 μl / well. The cell culture plate was placed in the incubator and continued to be cultured for 72 hours, and 60 μl / well of the supernatant was transferred to the TZM-bl cell plate (3×10 5 cells / ml, 100 μl / well), and then cultured for 24 h, adding 20 μl / well of Bright-Glo TM Luciferase detection reagent was shaken for 3 minutes, and then the luminescent signal was detected by a multifunctional microplate reader, and the relative virus level was calculated according to the following formula: relative virus level (%) = (luminescent value of experimental well - luminescent value of negative control well) / (luminescent value of positive control well - luminescent value of negative control well) × 100%.
[0070] (3) Experimental results
[0071] like Figure 4 As shown, in MT-2-HIV-1 IIIB In the cell infection model, the cell activity of homoplanin at the highest experimental concentration was less than 50%, and it had a certain degree of cytotoxicity to MT-2 cells, with the maximum non-toxic concentration being 200 μmol / L (see Figure 4 A), AZT had no effect on the activity of MT-2 cells at the maximum experimental concentration (10 μmol / L) (see Figure 4C, Table 1). Within the concentration range that does not affect cell activity, homophyllium can reduce the relative viral level of HIV-1 in MT-2 cells, and as the concentration of the compound increases, the relative viral amount decreases, that is, the inhibition rate increases.
[0072] Example 4
[0073] This example introduces the mechanism of action of psyllium glycosides in anti-AIDS drugs. Please refer to Figure 5 As shown, further introduction is given based on the above embodiments:
[0074] Experiment 3: Cytotoxicity and anti-HIV-1 activity of psyllium glycoside in peripheral blood mononuclear cells (PBMCs).
[0075] (1) Cytotoxicity assay
[0076] PBMCs were taken after PHA stimulation for 3 days, and RPMI1640 complete culture medium containing 100 U / ml IL-2 was added to adjust the cell population to 2×10 6 / ml, inoculated in a 96-well cell culture plate at a volume of 100μl / well, and added serially diluted compounds (40μl / well), with 3 replicate wells at the same concentration. Cells without compound treatment were used as negative controls, and culture fluid was used as background controls. Culture fluid was added to each well to a total volume of 200μl. Placed in an incubator for 12h, removed and washed three times with PBS, and then added with the original volume of fresh culture fluid and placed back in the incubator for continued culture for 120h. Add 20μl / well of The cell viability detection reagent was shaken for 3 minutes, placed in an incubator and incubated for 10 minutes, and finally the luminescent signal was detected on a multifunctional microplate reader, and the relative cell activity was calculated according to the following formula: cell activity (%) = (luminescence value of the experimental well-luminescence value of the background well) / (luminescence value of the negative control well-luminescence value of the background well) × 100%.
[0077] (2) Antiviral activity test
[0078] PBMCs were taken after PHA stimulation for 3 days, and RPMI1640 complete culture medium containing 100 U / ml IL-2 was added to adjust the cell population to 2×10 6 / ml, inoculated in a 96-well cell culture plate at a volume of 100 μl / well, and serially diluted compounds (40 μl / well) and appropriately diluted HIV-1 BalVirus stock solution (p24: 44ng / ml), set up 3 replicate wells at the same concentration. No compound was added to the positive control well, and the culture medium was supplemented to a total volume of 200μl / well. After the cell plate was placed in the incubator for 12h, it was taken out and washed three times with PBS, and the original volume of fresh culture medium was added, and then returned to the incubator. After continuing to culture for 120h, the supernatant was collected, and the HIV-1p24 content was detected by ELISA, and the relative virus level was calculated according to the following formula: Relative virus level (%) = p24 content in experimental well / p24 content in positive control well × 100%.
[0079] (3) Experimental results
[0080] like Figure 5 As shown in A, homoplanin had no cytotoxicity to PBMCs within the experimental concentration range, and within the non-toxic concentration range, the HIV-1p24 level decreased compared with the virus-infected group. Figure 5 As shown in B, at the maximum experimental concentration of AZT (2 μmol / L), the activity of PBMCs did not decrease significantly, and the relative level of HIV-1p24 decreased compared with the virus-infected group. Homophytoside showed a dose-dependent anti-HIV-1 activity similar to AZT within the non-toxic concentration range.
[0081] Example 5
[0082] This example introduces the mechanism of action of psyllium glycosides in anti-AIDS drugs. Please refer to Figure 6 As shown, further introduction is given based on the above embodiments:
[0083] Experiment 4: Inhibitory effect of homoplanin on HIV-1-induced cytopathic effect (CPE)
[0084] After MT-2 cells are infected with HIV-1 virus, they will be induced to produce cytopathic effect (CPE) and form syncytia. Through the fully automatic cell imaging instrument, we can observe the cytopathic effect produced by different concentrations of homoplanin and AZT, and compare with the pure HIV-1 infection group (positive control group) and pure cell group (negative control group) to evaluate the inhibitory effect of the compound on syncytia formation. Figure 6 (The formation of syncytia was observed under a microscope, as indicated by the red arrows in the figure) and as shown in Table 2, a large number of syncytia were formed in the HIV-1 infection group without compound treatment, and no syncytia were formed in the negative control group. In the high-plantaginosides groups with different concentrations, as the concentration of the compound increased, the number of syncytia formed decreased accordingly. Compared with the HIV-1 infection group, at concentrations of 200 μmol / L and 40 μmol / L, the high-plantaginosides group formed fewer syncytia, indicating that high-plantaginosides can reduce HIV-1-induced syncytia within a certain concentration range.
[0085] Table 1 Summary of in vitro cytotoxicity and anti-HIV-1 activity data of homoplanin
[0086]
[0087] (IC 50 : The drug concentration that can effectively inhibit 50% of the virus)
[0088] Table 2 Inhibition of HIV-1-induced CPE by homoplanin
[0089]
[0090] Homophytoside in TZM-b-HIV-1 IIIB MT-2-HIV-1 IIIB and PBMCs-HIV-1 Bal In all models, HIV-1 virus levels can be reduced within a safe concentration range without cytotoxicity, and the SI values are shown in Table 1. The SI values of homoplanin in the three models are all greater than 20. Based on this, this study will continue to explore its anti-HIV-1 mechanism of action.
[0091] Example 6
[0092] This example introduces the mechanism of action of psyllium glycosides in anti-AIDS drugs. Please refer to Figure 7 As shown, further introduction is given based on the above embodiments:
[0093] Experiment 5: In vitro inhibition of HIV-1 key enzyme activity by homoplanin
[0094] The above cell experiments showed that homophytoside has certain anti-HIV-1 activity, so the enzyme ELISA kit was used to further detect the effect of homophytoside on the activity of HIV-1 integrase (IN), reverse transcriptase (RT) and protease (PR). Figure 7 A The results showed that homoplanin could reduce the activity of HIV-1 reverse transcriptase. At the maximum experimental concentration, the reverse transcriptase activity was less than 40%, and the enzyme activity gradually increased with the decrease of compound concentration. Figure 7 As shown in Figure B, homoplanin can also inhibit HIV-1 protease activity within a certain concentration range. At the highest experimental concentration, the protease activity was less than 20%, and the inhibitory effect gradually decreased with the decrease of concentration. Figure 7 As shown in C, homoplanin had no significant inhibitory effect on HIV-1 integrase activity.
[0095] The above description is only the preferred embodiment of the present invention, which does not limit the protection scope of the present invention. For those skilled in the art, the present invention can be modified and varied in various ways. Within the spirit and principle of the present invention, any change, modification, replacement, integration and parameter change of these embodiments by conventional substitution or capable of achieving the same function without departing from the principle and spirit of the present invention shall fall within the protection scope of the present invention.
Claims
1. Application of psyllium glycosides in the preparation of drugs for the prevention and treatment of AIDS, It is characterized in that Homoplanginosid is used to prepare a homoplanginosid derivative or a composite drug containing homoplanginosid. The structural formula of the homoplanginosid is as follows:
2. The use of the psyllium glycoside according to claim 1 in the preparation of drugs for preventing and treating AIDS, It is characterized in that The AIDS is HIV-1 type.
3. The use of the psyllium glycoside according to claim 2 in the preparation of drugs for preventing and treating AIDS, It is characterized in that The homoplanin and pharmaceutically acceptable auxiliary materials form a preparation.
4. The use of the psyllium glycoside according to claim 3 in the preparation of drugs for preventing and treating AIDS, It is characterized in that The dosage forms of the preparation include injection, capsule, tablet, granule, dragee and solution.
5. Use of the psyllium glycoside according to claim 4 in the preparation of drugs for preventing and treating AIDS, It is characterized in that The dosage forms include commonly used excipients and pharmaceutical excipients; The commonly used excipients include fillers and solubilizers, binders, humectants, disintegrants, absorbents, and lubricants; The pharmaceutical excipients include solid, semi-solid and liquid forms.
